Has Victoria Ryvkin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,724 in general payments to Victoria Ryvkin, MD across 93 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Victoria Ryvkin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Victoria Ryvkin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Victoria Ryvkin, MD

Endocrinology, Diabetes & Metabolism · Mt Prospect, ILNPI 1881815173

Payments from drug & device makers

$2,724in general payments, 2019–2025

Across 93 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Tandem Diabetes Care, Inc.$2K
Dexcom, Inc.$789
Novo Nordisk$62

What the payments were for

Travel & lodging$1,31548%
Food & beverage$1,40852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Tandem Diabetes Care, Inc.	3	$1,872
Dexcom, Inc.	89	$789
Novo Nordisk	1	$62

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

t:slim X2 Insulin Pump with Control-IQ$1,785
DEXCOM G6 TRANSMITTER$174

How this compares

$2,724 in reported general payments places this provider in the 65th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024

$162,585

Medicare patients

507

Services billed

2,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	555	$1,040,812
MounjaroTirzepatide	280	$415,797
JardianceEmpagliflozin	252	$303,011
TrulicityDulaglutide	239	$300,122
FarxigaDapagliflozin Propanediol	164	$179,442
Fiasp FlextouchInsulin Aspart (Niacinamide)	65	$67,153
Humalog Kwikpen U-200Insulin Lispro	23	$60,103
Humalog Kwikpen U-100Insulin Lispro	138	$39,774
JanuviaSitagliptin Phosphate	39	$39,552
Humulin R U-500 KwikpenInsulin Regular, Human	33	$31,781
Tresiba Flextouch U-100Insulin Degludec	73	$30,775
RybelsusSemaglutide	17	$30,138
Nano 2nd Gen Pen NeedlePen Needle, Diabetic	214	$28,821
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	23	$28,038
Novolog FlexpenInsulin Aspart	86	$23,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Rybelsus	$62	$1,070,950572 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

Other endocrinology, diabetes & metabolism in Mt Prospect

Liana BillingsSkokie$3.4M
Leon FogelfeldChicago$1.5M
Grazia AleppoChicago$1.4M
Wahid KassarChicago$884K
Anthony PickLake Forest$665K
Hiralal MaheshwariMcHenry$642K
Wenyu HuangChicago$639K
Babak PazookiJoliet$582K
Silvana PannainChicago$575K
Ammar BayrakdarEvergreen Park$517K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →